Search Result
Results for "
lung function
" in MedChemExpress (MCE) Product Catalog:
3
Biochemical Assay Reagents
1
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-101083
-
|
|
Bcl-2 Family
|
Cancer
|
|
BDA-366 is a potent Bcl2 antagonist (Ki = 3.3 nM), binding Bcl2-BH4 domain with high affinity and selectivity. BDA-366 induces conformational change in Bcl2 that abrogates its antiapoptotic function, converting it from a survival molecule to a cell death inducer. BDA-366 suppresses growth of lung cancer cells .
|
-
-
- HY-109187A
-
|
PTI-801 sodium
|
CFTR
|
Inflammation/Immunology
|
|
Posenacaftor (PTI-801) sodium is a cystic fibrosis transmembrane regulator (CFTR) protein modulator that corrects the folding and trafficking of CFTR protein. Posenacaftor sodium is used for the research of cystic fibrosis (CF) .
|
-
-
- HY-P1624
-
|
ALX-0600
|
Nuclear Hormone Receptor 4A/NR4A
FXR
|
Inflammation/Immunology
|
|
Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .
|
-
-
- HY-109187B
-
|
(R)-PTI-801 sodium
|
CFTR
|
Inflammation/Immunology
|
|
(R)-Posenacaftor (R)-PTI-801) sodium is the R enantiomer of Posenacaftor. Posenacaftor is a cystic fibrosis transmembrane regulator (CFTR) protein modulator that corrects the folding and trafficking of CFTR protein. Posenacaftor is used for the research of cystic fibrosis (CF) .
|
-
-
- HY-P1624A
-
|
ALX-0600 TFA
|
Nuclear Hormone Receptor 4A/NR4A
FXR
|
Inflammation/Immunology
|
|
Teduglutide TFA is a dipeptidyl peptidase IV resistant glucagon-like peptide 2 (GLP-2) analogue. Teduglutide TFA can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide TFA can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .
|
-
-
- HY-164021
-
|
BR-222; UR389
|
Drug Derivative
|
Others
|
|
Brovanexine hydrochloride (BR-222; UR389) is an expectorant, which reduces the adsorption capacity of sputum and ameliorates lung ventilation function .
|
-
-
- HY-109187
-
|
PTI-801
|
CFTR
|
Inflammation/Immunology
|
|
Posenacaftor (PTI-801) is a cystic fibrosis transmembrane regulator (CFTR) protein modulator that corrects the folding and trafficking of CFTR protein. Posenacaftor is used for the research of cystic fibrosis (CF) .
|
-
-
- HY-121571
-
|
|
Others
|
Infection
Cancer
|
|
Prallethrin, a spatial mosquito repellent, is a non-fluorinated pyrethroid targeting lung surfactant proteins (SPs). prallethrin has vapor toxicity and can bind with the lung SPs by hydrogen and hydrophobic interactions, impairing functions of SPs. Prallethrin can be used for respiratory illness, pathogenic infections and malignancy research .
|
-
-
- HY-106377
-
|
|
MARCKS
|
Inflammation/Immunology
|
|
BIO-11006 is a peptide that inhibits the function of the MARCKS protein. BIO-11006 attenuates LPS-induced neutrophil influx into the lungs, NF-κB activation, and expression of the proinflammatory cytokines KC and TNF-α. BIO-11006 also reverses disease progression in an LPS-induced mouse lung injury model. BIO-11006 is indicated for research on acute lung injury/acute respiratory distress syndrome (ALI/ARDS) .
|
-
-
- HY-W838254
-
|
|
PKC
Endogenous Metabolite
|
Others
|
|
1,2-Dipentadecanoyl-sn-glycero-3-phospho-(1'-rac-glycerol) sodium functions as an activator for the protein kinase C family and is an anionic phospholipid found in mitochondrial and microsomal membranes, playing a crucial role in the composition of lung surfactant, particularly within the membranes of lamellar bodies in the lungs.
|
-
-
- HY-150229
-
|
|
Liposome
|
Cancer
|
|
306-N16B is a selective lung-targeted lipid nanoparticle that reversibly targets lung endothelial cells and specific immune cells through selective adsorption of a protein corona mediated by differences in tail structure (such as fibrinogen β/γ chain). 306-N16B binds to specific plasma proteins in the blood to form a protein corona, which guides the particles to be enriched in the lungs, releases mRNA and promotes target cell gene expression, exerts efficient lung cell transfection activity, and can precisely regulate gene delivery of different cell types in the lungs (such as endothelial cells and macrophages). 306-N16B can be used in gene therapy technologies for hereditary lung diseases including pulmonary lymphangioleiomyomatosis (LAM), restoring tumor suppressor function by delivering Tsc2 mRNA, and can also be used for lung-specific mRNA vaccines and gene editing therapies .
|
-
-
- HY-159686
-
|
|
Adrenergic Receptor
|
Inflammation/Immunology
Endocrinology
|
|
Aclidinium is a long-acting muscarinic antagonist and long-acting β2-adrenoceptor (β2-AR) agonist with bronchodilator activity. Aclidinium can reduce hyperinflation of the lungs and increase lung function and exercise endurance time. Aclidinium is used in research on chronic obstructive pulmonary disease (COPD) .
|
-
-
- HY-14299D
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Indacaterol acetate is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol acetate inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol acetate can also be used in cardiovascular disease research .
|
-
-
- HY-14299
-
|
|
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Indacaterol is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol can also be used in cardiovascular disease research .
|
-
-
- HY-14299C
-
|
|
Adrenergic Receptor
|
Inflammation/Immunology
|
|
Indacaterol xinafoate is an orally active long-acting β2-adrenergic agonist (LABA) with bronchodilatory effect. Indacaterol inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol xinafoate can be utilized in asthma research .
|
-
-
- HY-14299A
-
|
QAB149
|
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Indacaterol maleate (QAB149) is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol maleate inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol maleate can also be used in cardiovascular disease research .
|
-
-
- HY-W839203
-
|
1,2-Didocosanoyl-sn-glycero-3-phosphocholine; PC(22:0/22:0)
|
Endogenous Metabolite
|
Others
|
|
22:0 PC (1,2-Didocosanoyl-sn-glycero-3-phosphocholine), a type of phosphatidylcholine, functions as a lung surfactant and is characterized as an amphipathic molecule predominantly found in the outer leaflets of biological membrane bilayers.
|
-
-
- HY-W005379
-
|
|
TGF-beta/Smad
|
Inflammation/Immunology
|
|
DGM is an inhibitor of the TGF-β1/Smad signaling pathway with significant antifibrotic effects. DGM inhibits the epithelial-mesenchymal transition (EMT) process in alveolar epithelial cells and slows the progression of pulmonary fibrosis in vivo by reducing lung inflammation, improving lung function, and decreasing extracellular matrix (ECM) remodeling. DGM can be used in research on idiopathic pulmonary fibrosis (IPF) and EMT-related diseases .
|
-
-
- HY-14299R
-
|
|
Reference Standards
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Indacaterol (Standard) is the analytical standard of Indacaterol. This product is intended for research and analytical applications. Indacaterol is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol can also be used in cardiovascular disease research .
|
-
-
- HY-14299AR
-
|
QAB149 (Standard)
|
Reference Standards
Adrenergic Receptor
|
Cardiovascular Disease
Endocrinology
Cancer
|
|
Indacaterol (maleate) (Standard) is the analytical standard of Indacaterol (maleate). This product is intended for research and analytical applications. Indacaterol maleate (QAB149) is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol maleate inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol maleate can also be used in cardiovascular disease research .
|
-
-
- HY-145603
-
|
VX-121
|
CFTR
Chloride Channel
|
Neurological Disease
|
|
Vanzacaftor (VX-121) is an orally active noval corrector of Cystic fibrosis transmembrane conductance regulator (CFTR). Vanzacaftor improves processing and trafficking of CFTR protein as well as increases chloride transport in triple combined with Tezacaftor (HY-15448) and Deutivacaftor. Vanzacaftor-Tezacaftor-Deutivacaftor is safe and well tolerated, improving lung function, respiratory symptoms, and CFTR function with cystic fibrosis, which is promising for research in the field of cystic fibrosis diseases .
|
-
-
- HY-157796
-
|
|
Adrenergic Receptor
|
Metabolic Disease
|
|
β2AR agonist 4 (compound A19) is a potent and selective β2-Adrenoceptor agonist with an EC50 of 3.7 pM. β2AR agonist 4 suppresses the inflammatory cytokines and leukocytes upregulation and improves lung function in COPD rat model .
|
-
-
- HY-151537
-
|
|
Fluorescent Dye
|
Infection
Inflammation/Immunology
|
|
Gol-NTR is a Golgi-targetable probe with high selectivity and sensitivity. Gol-NTR is Nitroreductase (NTR)-activated and has visualization acute lung injury (ALI) and repair function. Gol-NTR has a low detection limit of 54.8 ng/mL. Gol-NTR can be used for the research for monitoring and assessing research response of sepsis-induced ALI .
|
-
-
- HY-124653
-
|
J2
|
HSP
|
Cancer
|
|
HSP27 inhibitor J2 (J2) is a HSP27 inhibitor, which significantly induces abnormal HSP27 dimer formation and inhibits a production of HSP27 giant polymers, thereby having an effect of inhibiting a chaperone function of the HSP27 and reducing a cell protection function thereof. HSP27 inhibitor J2 (J2) remarkably enhances the antiproliferative activity of 17-AAG and sensitizes cisplatin-induced lung cancer cell growth inhibition .
|
-
-
- HY-103193
-
|
Colforsin dapropate hydrochloride
|
Adenylate Cyclase
|
Cardiovascular Disease
|
|
NKH477 (Colforsin dapropate hydrochloride) directly activates the catalytic unit of adenylate cyclase and increases intracellular cAMP. NKH477 is a forskolin derivative that improves cardiac failure mainly through its beneficial effects on diastolic cardiac function. NKH477 exerts an antiproliferative effect in vivo with an altered cytokine profile to inhibit the acute rejection of rat orthotopic lung allografts .
|
-
-
- HY-137561A
-
|
PLN-74809 hydrochloride
|
Integrin
|
Inflammation/Immunology
|
|
Bexotegrast hydrochloride (PLN-74809 hydrochloride) is a small molecule dual selective inhibitor with activity targeting αVβ1 and αVβ6. Bexotegrast hydrochloride is used for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC). Bexotegrast hydrochloride inhibits the activation of TGF-β1 by blocking the function of these integrins, thereby preventing the growth of fibrous tissue in the lungs and bile ducts .
|
-
-
- HY-P990748
-
|
SAR443765
|
Interleukin Related
|
Inflammation/Immunology
|
|
Lunsekimig (SAR443765) is an anti-TSLP/IL13/ALB nonobody composed of 5 sequentially linked variable region heavy chains. Lunsekimig decreases blood eosinophils and lowers plasma levels of IL-5, eotaxin-3, and IgE. Lunsekimig also improves lung function. Lunsekimig can be used for the study and treatment of type 2 inflammatory asthma .
|
-
-
- HY-145603S
-
|
VX-121-d4
|
Isotope-Labeled Compounds
CFTR
Chloride Channel
|
Neurological Disease
|
|
Vanzacaftor-d4 (VX-121-d4) is the deuterium labeled Vanzacaftor (HY-145603). Vanzacaftor is an orally active noval corrector of Cystic fibrosis transmembrane conductance regulator (CFTR). Vanzacaftor improves processing and trafficking of CFTR protein as well as increases chloride transport in triple combined with Tezacaftor (HY-15448) and Deutivacaftor. Vanzacaftor-Tezacaftor-Deutivacaftor is safe and well tolerated, improving lung function, respiratory symptoms, and CFTR function with cystic fibrosis, which is promising for research in the field of cystic fibrosis diseases .
|
-
-
- HY-E70713
-
|
|
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
|
EML4-ALK is a fusion-type protein tyrosine kinase produced through gene rearrangement. EML4-ALK is a potential molecular target in non-small cell lung carcinoma (NSCLC). EML4 ALK Recombinant Human Active Protein Kinase is a recombinant EML4 ALK protein that can be used to study EML4 ALK-related functions .
|
-
-
- HY-E70646
-
|
|
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
|
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase in the insulin receptor superfamily. ALK can be used for the study of non-small cell lung carcinoma (NSCLC). ALK has multiple mutants. ALK L1196M Recombinant Human Active Protein Kinase is a recombinant ALK L1196M protein that can be used to study ALK L1196M-related functions .
|
-
-
- HY-E70644
-
|
|
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
|
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase in the insulin receptor superfamily. ALK can be used for the study of non-small cell lung carcinoma (NSCLC). ALK has multiple mutants. ALK F1174S Recombinant Human Active Protein Kinase is a recombinant ALK F1174S protein that can be used to study ALK F1174S-related functions .
|
-
-
- HY-E70642
-
|
|
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
|
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase in the insulin receptor superfamily. ALK can be used for the study of non-small cell lung carcinoma (NSCLC). ALK has multiple mutants. ALK C1156Y Recombinant Human Active Protein Kinase is a recombinant ALK C1156Y protein that can be used to study ALK C1156Y-related functions .
|
-
-
- HY-E70645
-
|
|
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
|
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase in the insulin receptor superfamily. ALK can be used for the study of non-small cell lung carcinoma (NSCLC). ALK has multiple mutants. ALK G1202R Recombinant Human Active Protein Kinase is a recombinant ALK G1202R protein that can be used to study ALK G1202R-related functions .
|
-
-
- HY-165603
-
|
|
Liposome
VEGFR
FGFR
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Si5-N14 is a key component of siloxane-incorporated lipid nanoparticles (SiLNP), possessing pro-vascular repair and anti-tumor activities. In the transgenic GFP mouse model, Si5-N14 can mediate CRISPR-Cas9 editing. In the Lewis lung carcinoma (LLC) tumor-bearing mouse model, Si5-N14 can knock out the expression of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) to exert an anti-tumor effect. In a mouse model of lung injury induced by viral infection, the delivery of Fibroblast Growth Factor-2 (FGF-2) mRNA via Si5-N14 can promote vascular repair, increase blood oxygen levels, and improve lung function. Si5-N14 shows promise for research in the fields of oncology, pneumonia, and cardiovascular diseases .
|
-
-
- HY-173493
-
|
|
Anaplastic lymphoma kinase (ALK)
Apoptosis
Akt
mTOR
|
Cancer
|
|
ALK-IN-31 (Compound Ld-10) is an orally active ALK inhibitor (IC50: 1135 nM). ALK-IN-31 exhibits excellent antiproliferative activity against lung cancer H2228 cells with an IC50 value of 1.35 μM. ALK-IN-31 induces apoptosis and arrests cell proliferation in the G0/G1 phase by affecting mitochondrial function. ALK-IN-31 exerts its anti-tumor effect by downregulating the expression of p-AKT and p-mTOR in the PI3K-AKT-mTOR signaling pathway downstream of ALK. ALK-IN-31 can be used in the study of non-small cell lung cancer (NSCLC) .
|
-
-
- HY-E70720
-
|
|
FGFR
|
Cancer
|
|
FGFR3 activating mutations are drivers of malignancy in several human tissues, including bladder, lung, cervix, and blood. FGFR3 K650M is a mutant of FGFR3. FGFR3 K650M Recombinant Human Active Protein Kinase is a recombinant FGFR3 K650M protein that can be used to study FGFR3 K650M-related functions .
|
-
-
- HY-112868B
-
|
|
Arginase
NO Synthase
Integrin
|
Cardiovascular Disease
Metabolic Disease
Inflammation/Immunology
|
|
ABH (hydrochloride) is an orally active arginase inhibitor (Ki = 8.5 nM). ABH hydrochloride promotes NO production and reduces the expression of inflammatory response-related molecules (ICAM-1, VCAM-1, MCP-1). ABH hydrochloride improves erectile function, reduces lung damage, promotes wound healing, reduces arterial blood pressure, and improves vascular fibrosis .
|
-
-
- HY-157486
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
KMI169 is a potent and selective inhibitor targeting lysine methyl-transferase (KMT9) (IC50 = 0.05 μM, Kd = 0.025 μM). KMI169 functions as a bi-substrate inhibitor targeting the cofactor S-5’-adenosyl-L-methionine (SAM) and substrate binding pockets of KMT9. KMI169 can downregulate target genes involved in cell cycle regulation and impair proliferation of tumor cells by inhibiting KMT9. KMI169 is a valuable tool to probe cellular KMT9 functions and can be research for combating diseases including prostate, lung, colon, and invasive bladder cancer .
|
-
-
- HY-110088
-
|
|
MDM-2/p53
|
Cancer
|
|
SCH529074 is a potent and orally active p53 activator. SCH529074 binds specifically and conformation-dependently to p53 DBD ( DNA binding domain) with a Ki of 1-2 μM in a saturable manner. SCH529074 restores mutant p53 function and interrupts HDM2-mediated ubiquitination of wild Type p53. SCH529074 can be used for the study of non-small-cell lung carcinoma (NSCLC) .
|
-
-
- HY-E70719
-
|
|
FGFR
|
Cancer
|
|
FGFR3 activating mutations are drivers of malignancy in several human tissues, including bladder, lung, cervix, and blood. FGFR3 K650E is a mutant of FGFR3 that may be present in multiple myeloma cell lines. FGFR3 K650E Recombinant Human Active Protein Kinase is a recombinant FGFR3 K650E protein that can be used to study FGFR3 K650E-related functions .
|
-
-
- HY-139061
-
|
|
LPL Receptor
ROCK
|
Cancer
|
|
Palmitoyl 3-carbacyclic phosphatidic acid (HY-139061) is a palmitoylated Carba-like cyclophosphatidic acid and an analog of lysophosphatidic acid (LPA). Palmitoyl 3-carbacyclic phosphatidic acid has different functions from LPA and can inhibit the activation of RhoA and inhibit the migration of melanoma cells. Palmitoyl 3-carbacyclic phosphatidic acid effectively inhibited experimental lung metastasis and reduced the number of tumor nodules in a B16-F0 xenograft mouse model .
|
-
-
- HY-E70693
-
|
|
Discoidin Domain Receptor
|
Cancer
|
|
Discoidin domain receptor 2 (DDR2) is a sensor for collagen and by participating in migration, proliferation, and extracellular matrix remodeling. DDR2 N456S is a DDR2 mutation that may be present in non-small cell lung cancer. DDR2 N456S Recombinant Human Active Protein Kinase is a recombinant DDR2 N456S protein that can be used to study DDR2 N456S-related functions .
|
-
-
- HY-I0501
-
|
o-aminoacetophenone
|
Bacterial
Apoptosis
Atg8/LC3
p62
Autophagy
|
Infection
Inflammation/Immunology
|
|
2'-Aminoacetophenone is an orally active inducer of apoptosis and respiratory biomarker. 2'-Aminoacetophenone can be used to detect Pseudomonas aeruginosa infections in the lungs of cystic fibrosis patients. 2'-Aminoacetophenone can inhibit the protein levels of LC3BII and p62 in macrophages infected with pqsA or mvfR and regulate autophagy. 2'-Aminoacetophenone can disrupt mitochondrial function by inducing oxidative stress and apoptosis signaling, leading to dysfunction in mouse skeletal muscle .
|
-
-
- HY-170776
-
|
|
PDGFR
VEGFR
FGFR
Apoptosis
|
Cancer
|
|
AXL/Angiokinase-IN-1 (compound 11b) is an AXL/triple angiokinase inhibitor, IC50=3.75 nM (AXL expression). AXL/Angiokinase-IN-1 inhibits epithelial-mesenchymal transition (EMT) in Bxpc-3, blocking lung cancer cell metastasis. AXL/Angiokinase-IN-1 also inhibits vascular and fibroblast functions, promoting apoptosis (apoptosis) in cancer cells and fibroblasts. AXL/Angiokinase-IN-1 features low toxicity and good metabolic stability .
|
-
-
- HY-P991458
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
hu3S193 is a human IgG monoclonal antibody (mAb) targeting Lewis Y. hu3S193 has excellent immune effector function (complement-dependent cytotoxicity) (IC50: 1.0 μg/ml) and antibody-dependent cellular cytotoxicity (IC50: 5.0 μg/ml). hu3S193 can be used in small cell lung cancer (SCLC) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
-
- HY-149677
-
|
|
Mitochondrial Metabolism
|
Cancer
|
|
ZK53 is a selective activator of mitochondrial caseinolytic protease P (HsClpP) (EC50: 1.37?μM for α-casein hydrolysis by HsClpP). ZK53 is is inactive toward bacterial ClpP proteins. ZK53 induces apoptosis in H1703, H520 and SK-MES-1 cells. ZK53 induces dysregulation of mitochondrial functions in lung squamous cell carcinoma (LUSC) cells. ZK53 inhibits tumor growth in H1703 xenograft mouse model .
|
-
-
- HY-B2078
-
|
|
Neurokinin Receptor
|
Inflammation/Immunology
|
|
Eprazinone can enhance lung function and arterial oxygen levels and can be used in the study of chronic bronchitis. Higher doses of eprazinone increased phospholipid levels and decreased neutral lipid content in bronchoalveolar lavage (BAL) fluid, but had no effect on protein and cell levels in BAL. Eprazinone dose-dependently reduced short-circuit current (Isc), primarily by reducing chloride secretion at lower concentrations and affecting sodium and chloride transport at higher doses. Eprazinone may exert its anti-inflammatory effects by regulating BAL lipid composition and airway ion transport .
|
-
-
- HY-101083A
-
|
|
Bcl-2 Family
|
Cancer
|
|
(Rac)-BDA-366 (example 2) is the despinner of BDA-366 (HY-101083). BDA-366 is a potent Bcl-2 antagonist (Ki=3.3 nM), binding Bcl-2-BH4 domain with high affinity and selectivity. BDA-366 induces conformational change in Bcl-2 that abrogates its antiapoptotic function, converting it from a survival molecule to a cell death inducer. BDA-366 suppresses growth of lung cancer cells .
|
-
-
- HY-W010572
-
|
alpha-Thioglycerol
|
Biochemical Assay Reagents
|
Others
|
|
1-Thioglycerol, commonly used as a reducing agent in various biochemical and biophysical applications, especially in protein chemistry and molecular biology, it can protect proteins from oxidation and denaturation, and can reduce disulfide bonds to thiols base, which can then be modified or analyzed. In addition, 1-Thioglycerol has been investigated for potential medical applications, including as an inhibitor of cystic fibrosis, which may help improve the function of lung cells, and has also been studied for Used in the preparation of metal nanoparticles and as a stabilizer for certain pharmaceutical preparations.
|
-
-
- HY-P10226
-
|
|
Chloride Channel
CFTR
|
Endocrinology
|
|
PGD97 is a selective cyclic peptide inhibitor against CAL/CFTR interactions, with a KD value of 6 nM towards the CAL PDZ domain for its desulfide cyclized form. PGD97 (desulfide cyclized form) has selectivity ≥ 130-fold compared to NHERF1/2 PDZ domains. PGD97 is capable of stabilizing F508del-CFTR at the cell membrane and improving CFTR function required for proper fluid homeostasis in tne lung. PGD97 can be used for the research of cystic fibrosis .
|
-
- HY-173268
-
|
|
TAM Receptor
|
Cardiovascular Disease
Cancer
|
|
UNC9426 is a potent and selective TYRO3 inhibitor (IC50 = 2.1 nM), demonstrating 276-fold and 90-fold selectivity over MERTK and AXL, respectively. UNC9426 reduces platelet aggregation without increasing bleeding time and blocks TYRO3-dependent functions in tumor cells and macrophages. UNC9426 demonstrates a favorable safety profile with no significant increase in bleeding risk in vivo. UNC9426 can be used for functional studies of TYRO3-dependent phenotypes such as non-small cell lung cancer (NSCLC) .
|
-
- HY-N6727
-
|
Aspergillin
|
Apoptosis
PKA
NF-κB
Bacterial
Fungal
Antibiotic
|
Infection
Inflammation/Immunology
Cancer
|
|
Gliotoxin is a secondary metabolite, the most abundant mycotoxin secreted by A. fumigatus, inhibits the phagocytosis of macrophages and the immune functions of other immune cells . Gliotoxin inhibits inducible NF-κB activity by preventing IκB degradation, which consequently induces host-cell apoptosis . Gliotoxin activates PKA and increases intracellular cAMP concentration; modulates actin cytoskeleton rearrangement to facilitate A. fumigatus internalization into lung epithelial cells . Gliotoxin is a potent NOTCH2 transactivation inhibitor, can effectively induce apoptosis of chronic lymphocytic leukemia (CLL) cells .
|
-
- HY-E70714
-
|
|
Anaplastic lymphoma kinase (ALK)
|
Cancer
|
|
EML4-ALK is a fusion-type protein tyrosine kinase produced through gene rearrangement. EML4-ALK can be used for the study of non-small cell lung carcinoma (NSCLC) and neuroblastoma (NB). EML4-ALK has multiple mutants. EML4 ALK F1174L Recombinant Human Active Protein Kinase is a recombinant EML4 ALK F1174L protein that can be used to study EML4 ALK F1174L-related functions .
|
-
- HY-E70718
-
|
|
FGFR
|
Cancer
|
|
FGFR3 activating mutations are drivers of malignancy in several human tissues, including bladder, lung, cervix, and blood. FGFR3 G697C is a mutant of FGFR3 that may be present in oral squamous cell carcinoma. FGFR3 G697C increases FGFR3 auto-phosphorylation. FGFR3 G697C Recombinant Human Active Protein Kinase is a recombinant FGFR3 G697C protein that can be used to study FGFR3 G697C-related functions .
|
-
- HY-I0501R
-
|
o-aminoacetophenone (Standard)
|
Reference Standards
Bacterial
Apoptosis
Atg8/LC3
p62
Autophagy
|
Infection
Inflammation/Immunology
|
|
2'-Aminoacetophenone (Standard) is the analytical standard of 2'-Aminoacetophenone. This product is intended for research and analytical applications. 2'-Aminoacetophenone is an orally active inducer of apoptosis and respiratory biomarker. 2'-Aminoacetophenone can be used to detect Pseudomonas aeruginosa infections in the lungs of cystic fibrosis patients. 2'-Aminoacetophenone can inhibit the protein levels of LC3BII and p62 in macrophages infected with pqsA or mvfR and regulate autophagy. 2'-Aminoacetophenone can disrupt mitochondrial function by inducing oxidative stress and apoptosis signaling, leading to dysfunction in mouse skeletal muscle .
|
-
- HY-W010572R
-
|
alpha-Thioglycerol (Standard)
|
Biochemical Assay Reagents
Reference Standards
|
Others
|
|
1-Thioglycerol (Standard) is the analytical standard of 1-Thioglycerol. This product is intended for research and analytical applications. 1-Thioglycerol, commonly used as a reducing agent in various biochemical and biophysical applications, especially in protein chemistry and molecular biology, it can protect proteins from oxidation and denaturation, and can reduce disulfide bonds to thiols base, which can then be modified or analyzed. In addition, 1-Thioglycerol has been investigated for potential medical applications, including as an inhibitor of cystic fibrosis, which may help improve the function of lung cells, and has also been studied for Used in the preparation of metal nanoparticles and as a stabilizer for certain pharmaceutical preparations.
|
-
- HY-175206
-
|
|
P-glycoprotein
|
Cancer
|
|
P-gp-IN-30 (Compound 13) is a P-glycoprotein (P-gp) inhibitor by targeting YB-1. P-gp-IN-30 significantly enhances sensitivity to Paclitaxel by reducing total YB-1 and nucleus YB-1 protein expression, inhibiting the expression and function of downstream P-gp, further suppressing the efflux rate of Paclitaxel. P-gp-IN-30 potently inhibits tumor growth in A549/Taxol xenografts mice model with combination of Paclitaxel (HY-B0015). P-gp-IN-30 can be used for non-small cell lung cancer (NSCLC) research .
|
-
- HY-E70717
-
|
|
FGFR
|
Cancer
|
|
FGFR1 has been implicated in numerous cancer types including non-small cell lung cancer (NSCLC). FGFR1 is activated upon FGF binding to its extracellular domain, resulting in protein dimerization and transautophosphorylation of the intracellular tyrosine kinase domains. FGFR1 V561M gatekeeper mutation drives Fexagratinib (AZD4547) (HY-13330) resistance through STAT3 Activation and EMT. FGFR1 V561M Recombinant Human Active Protein Kinase is a recombinant FGFR1 V561M protein that can be used to study FGFR1 V561M-related functions .
|
-
- HY-P99157
-
|
|
CD276/B7-H3
|
Cancer
|
|
Omburtamab is a humanized monoclonal antibody targeting B7-H3 (CD276). Omburtamab selectively binds to B7-H3 highly expressed on the surface of tumor cells and activates anti-tumor immune responses mediated by T cells and natural killer (NK) cells. Omburtamab can promote the specific infiltration of CAR-T cells into tumors, enhance the killing function of NK cells through the CD16 signaling pathway, and regulate tumor cell glucose metabolism (such as inhibiting the Warburg effect). Omburtamab has the potential to inhibit solid tumors such as non-small cell lung cancer (NSCLC) .
|
-
- HY-129397
-
|
BPG; 2,3-Dinor-11β-PGF2α; 2,3-dinor-11-epi PGF2α
|
Prostaglandin Receptor
|
Endocrinology
|
|
2,3-Dinor-11beta-prostaglandin F2alpha (2,3-Dinor-11β-PGF2α) is a metabolite of PGD2. Urinary excretion of 2,3-Dinor-11beta-prostaglandin F2alpha is increased in patients with mast cell activation disease (MCAD) and has been used as a marker of increased PGD2 levels. 2,3-Dinor-11beta-prostaglandin F2alpha levels are also increased in the urine of patients with asthma and are positively correlated with impaired lung function.
|
-
- HY-108858
-
|
rhDNase
|
DNA/RNA Synthesis
Endonuclease
|
Inflammation/Immunology
|
|
Dornase alfa (rhDNase) is a recombinant human deoxyribonuclease I (rhDNase) that can specifically degrade extracellular DNA. Dornase alfa catalyzes the cleavage of DNA released by neutrophils in respiratory mucus, reduces sputum viscosity, thereby improving mucus clearance efficiency, reducing airway obstruction and alleviating inflammatory responses. Dornase alfa can be used to improve lung function (such as FEV_1) in cystic fibrosis (CF), reduce the risk of acute pulmonary exacerbations, and has good in vivo tolerability. Dornase alfa acts locally on the respiratory tract through aerosol inhalation, specifically improving the high viscosity of mucus caused by DNA accumulation and related respiratory symptoms .
|
-
- HY-P99117
-
|
AK104
|
PD-1/PD-L1
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC) .
|
-
- HY-175033
-
|
|
Epigenetic Reader Domain
Phosphatase
c-Myc
Apoptosis
|
Inflammation/Immunology
|
|
BRD4-IN-11 is an orally active and selective BRD4 inhibitor (IC50 = 26.35 nM (BD1), IC50 = 72.81 nM (BD2)). BRD4-IN-11 is approximately 3- to 18-fold more potent against BRD4 than againstBRD2, BRD3, and BRDT. BRD4-IN-11 enhances H2S release and inhibits the upregulation of fibrotic markers (α-SMA and fibronectin), c-Myc, and CDC25B. BRD4-IN-11 reduces apoptosis in LO2 hepatocytes. BRD4-IN-11 significantly improves liver and lung function in a hepatopulmonary fibrosis model and can be used to study hepatopulmonary fibrosis .
|
-
- HY-N1508
-
|
|
MMP
Apoptosis
Autophagy
NF-κB
TNF Receptor
COX
Toll-like Receptor (TLR)
SOD
ASK1
JNK
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
Ecliptasaponin A is an orally active pentacyclic triterpenoid saponin. Ecliptasaponin A exerts anti-tumor activity by activating ASK1/JNK pathway, inducing apoptosis and autophagy in lung cancer cells. Ecliptasaponin A exerts anti-inflammatory/anti-fibrotic effects and protects the cardiovascular system by inhibiting the HMGB1/TLR4/NF-κB pathway, and the expression of COX-2 and MMP-9. Ecliptasaponin A can enhance SOD activity, reduce MDA levels, and alleviate oxidative stress damage. Ecliptasaponin A exerts chondroprotective effects by inhibiting the expression of MMP13 and regulating inflammatory factors. Ecliptasaponin A improves ovarian function and regulates sex hormones by upregulating the expression of ESR1 receptors .
|
-
- HY-N3225
-
|
|
NAMPT
Sirtuin
Microtubule/Tubulin
Apoptosis
Autophagy
PDGFR
NF-κB
AMPK
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Myricanol is a diarylheptanoid and a Nampt activator. Myricanol exerts anti-inflammatory effects and alleviates glucocorticoid-induced muscle atrophy by increasing Sirtuin 1 (SIRT1) and PRDX5 activities while regulating inflammatory factors. Myricanol exhibits growth inhibition and induces apoptosis in human lung adenocarcinoma A549 cells. Myricanol promotes autophagy-mediated clearance of microtubule-associated protein tau to exert neuroprotective effects. Myricanol protects cardiovascular function by inhibiting PDGFRβ and NF-κB signaling pathways. Myricanol activates mitochondrial transcription factor A (TFAM) expression to exert anti-renal fibrosis effects. Myricanol improves insulin resistance through AMPK activation .
|
-
- HY-N1508R
-
|
|
Reference Standards
MMP
Apoptosis
Autophagy
NF-κB
TNF Receptor
COX
Toll-like Receptor (TLR)
SOD
ASK1
JNK
|
Cardiovascular Disease
Inflammation/Immunology
Endocrinology
Cancer
|
|
Ecliptasaponin A (Standard) is the analytical standard for Ecliptasaponin A (HY-N1508). Ecliptasaponin A is an orally active pentacyclic triterpenoid saponin. Ecliptasaponin A exerts anti-tumor activity by activating ASK1/JNK pathway, inducing apoptosis and autophagy in lung cancer cells. Ecliptasaponin A exerts anti-inflammatory/anti-fibrotic effects and protects the cardiovascular system by inhibiting the HMGB1/TLR4/NF-κB pathway, and the expression of COX-2 and MMP-9. Ecliptasaponin A can enhance SOD activity, reduce MDA levels, and alleviate oxidative stress damage. Ecliptasaponin A exerts chondroprotective effects by inhibiting the expression of MMP13 and regulating inflammatory factors. Ecliptasaponin A improves ovarian function and regulates sex hormones by upregulating the expression of ESR1 receptors.
|
-
- HY-161577
-
|
|
Bcl-2 Family
|
Cancer
|
|
BFC1103 is a small-molecule compound whose primary mechanism of action involves interaction with a specific domain of Bcl-2, particularly its loop domain. This interaction induces a conformational change in Bcl-2, exposing its BH3 (Bcl-2 homology 3) domain, thereby switching Bcl-2's function from anti-apoptotic to pro-apoptotic. The cell death induced by BFC1103 is dependent on the presence of Bax or Bak, both of which are key proteins involved in the intrinsic apoptotic pathway mediated by mitochondria. BFC1103 has successfully inhibited lung metastasis of triple-negative breast cancer in mouse models. It can be utilized in studying the roles of Bcl-2 family proteins in cancer development and how they impact the survival and proliferation of cancer cells .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-151537
-
|
|
Fluorescent Dyes/Probes
|
|
Gol-NTR is a Golgi-targetable probe with high selectivity and sensitivity. Gol-NTR is Nitroreductase (NTR)-activated and has visualization acute lung injury (ALI) and repair function. Gol-NTR has a low detection limit of 54.8 ng/mL. Gol-NTR can be used for the research for monitoring and assessing research response of sepsis-induced ALI .
|
| Cat. No. |
Product Name |
Type |
-
- HY-150229
-
|
|
Drug Delivery
|
|
306-N16B is a selective lung-targeted lipid nanoparticle that reversibly targets lung endothelial cells and specific immune cells through selective adsorption of a protein corona mediated by differences in tail structure (such as fibrinogen β/γ chain). 306-N16B binds to specific plasma proteins in the blood to form a protein corona, which guides the particles to be enriched in the lungs, releases mRNA and promotes target cell gene expression, exerts efficient lung cell transfection activity, and can precisely regulate gene delivery of different cell types in the lungs (such as endothelial cells and macrophages). 306-N16B can be used in gene therapy technologies for hereditary lung diseases including pulmonary lymphangioleiomyomatosis (LAM), restoring tumor suppressor function by delivering Tsc2 mRNA, and can also be used for lung-specific mRNA vaccines and gene editing therapies .
|
-
- HY-W010572
-
|
alpha-Thioglycerol
|
Biochemical Assay Reagents
|
|
1-Thioglycerol, commonly used as a reducing agent in various biochemical and biophysical applications, especially in protein chemistry and molecular biology, it can protect proteins from oxidation and denaturation, and can reduce disulfide bonds to thiols base, which can then be modified or analyzed. In addition, 1-Thioglycerol has been investigated for potential medical applications, including as an inhibitor of cystic fibrosis, which may help improve the function of lung cells, and has also been studied for Used in the preparation of metal nanoparticles and as a stabilizer for certain pharmaceutical preparations.
|
-
- HY-W010572R
-
|
alpha-Thioglycerol (Standard)
|
Biochemical Assay Reagents
|
|
1-Thioglycerol (Standard) is the analytical standard of 1-Thioglycerol. This product is intended for research and analytical applications. 1-Thioglycerol, commonly used as a reducing agent in various biochemical and biophysical applications, especially in protein chemistry and molecular biology, it can protect proteins from oxidation and denaturation, and can reduce disulfide bonds to thiols base, which can then be modified or analyzed. In addition, 1-Thioglycerol has been investigated for potential medical applications, including as an inhibitor of cystic fibrosis, which may help improve the function of lung cells, and has also been studied for Used in the preparation of metal nanoparticles and as a stabilizer for certain pharmaceutical preparations.
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1624
-
|
ALX-0600
|
Nuclear Hormone Receptor 4A/NR4A
FXR
|
Inflammation/Immunology
|
|
Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .
|
-
- HY-P1624A
-
|
ALX-0600 TFA
|
Nuclear Hormone Receptor 4A/NR4A
FXR
|
Inflammation/Immunology
|
|
Teduglutide TFA is a dipeptidyl peptidase IV resistant glucagon-like peptide 2 (GLP-2) analogue. Teduglutide TFA can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide TFA can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis .
|
-
- HY-P10226
-
|
|
Chloride Channel
CFTR
|
Endocrinology
|
|
PGD97 is a selective cyclic peptide inhibitor against CAL/CFTR interactions, with a KD value of 6 nM towards the CAL PDZ domain for its desulfide cyclized form. PGD97 (desulfide cyclized form) has selectivity ≥ 130-fold compared to NHERF1/2 PDZ domains. PGD97 is capable of stabilizing F508del-CFTR at the cell membrane and improving CFTR function required for proper fluid homeostasis in tne lung. PGD97 can be used for the research of cystic fibrosis .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P990748
-
|
SAR443765
|
Interleukin Related
|
Inflammation/Immunology
|
|
Lunsekimig (SAR443765) is an anti-TSLP/IL13/ALB nonobody composed of 5 sequentially linked variable region heavy chains. Lunsekimig decreases blood eosinophils and lowers plasma levels of IL-5, eotaxin-3, and IgE. Lunsekimig also improves lung function. Lunsekimig can be used for the study and treatment of type 2 inflammatory asthma .
|
-
- HY-P99157
-
|
|
CD276/B7-H3
|
Cancer
|
|
Omburtamab is a humanized monoclonal antibody targeting B7-H3 (CD276). Omburtamab selectively binds to B7-H3 highly expressed on the surface of tumor cells and activates anti-tumor immune responses mediated by T cells and natural killer (NK) cells. Omburtamab can promote the specific infiltration of CAR-T cells into tumors, enhance the killing function of NK cells through the CD16 signaling pathway, and regulate tumor cell glucose metabolism (such as inhibiting the Warburg effect). Omburtamab has the potential to inhibit solid tumors such as non-small cell lung cancer (NSCLC) .
|
-
- HY-P99117
-
|
AK104
|
PD-1/PD-L1
CTLA-4
|
Inflammation/Immunology
Cancer
|
|
Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC) .
|
-
- HY-P991458
-
|
|
Transmembrane Glycoprotein
|
Cancer
|
|
hu3S193 is a human IgG monoclonal antibody (mAb) targeting Lewis Y. hu3S193 has excellent immune effector function (complement-dependent cytotoxicity) (IC50: 1.0 μg/ml) and antibody-dependent cellular cytotoxicity (IC50: 5.0 μg/ml). hu3S193 can be used in small cell lung cancer (SCLC) research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-I0501
-
-
-
- HY-N6727
-
-
-
- HY-I0501R
-
|
o-aminoacetophenone (Standard)
|
Structural Classification
Microorganisms
Ketones, Aldehydes, Acids
Source classification
|
Reference Standards
Bacterial
Apoptosis
Atg8/LC3
p62
Autophagy
|
|
2'-Aminoacetophenone (Standard) is the analytical standard of 2'-Aminoacetophenone. This product is intended for research and analytical applications. 2'-Aminoacetophenone is an orally active inducer of apoptosis and respiratory biomarker. 2'-Aminoacetophenone can be used to detect Pseudomonas aeruginosa infections in the lungs of cystic fibrosis patients. 2'-Aminoacetophenone can inhibit the protein levels of LC3BII and p62 in macrophages infected with pqsA or mvfR and regulate autophagy. 2'-Aminoacetophenone can disrupt mitochondrial function by inducing oxidative stress and apoptosis signaling, leading to dysfunction in mouse skeletal muscle .
|
-
-
- HY-N1508
-
-
-
- HY-N3225
-
|
|
Myrica ceriferaL.
Structural Classification
Source classification
Phenols
Polyphenols
Plants
Myricaceae
|
NAMPT
Sirtuin
Microtubule/Tubulin
Apoptosis
Autophagy
PDGFR
NF-κB
AMPK
|
|
Myricanol is a diarylheptanoid and a Nampt activator. Myricanol exerts anti-inflammatory effects and alleviates glucocorticoid-induced muscle atrophy by increasing Sirtuin 1 (SIRT1) and PRDX5 activities while regulating inflammatory factors. Myricanol exhibits growth inhibition and induces apoptosis in human lung adenocarcinoma A549 cells. Myricanol promotes autophagy-mediated clearance of microtubule-associated protein tau to exert neuroprotective effects. Myricanol protects cardiovascular function by inhibiting PDGFRβ and NF-κB signaling pathways. Myricanol activates mitochondrial transcription factor A (TFAM) expression to exert anti-renal fibrosis effects. Myricanol improves insulin resistance through AMPK activation .
|
-
-
- HY-N1508R
-
|
|
Triterpenes
Structural Classification
other families
Terpenoids
Source classification
Plants
|
Reference Standards
MMP
Apoptosis
Autophagy
NF-κB
TNF Receptor
COX
Toll-like Receptor (TLR)
SOD
ASK1
JNK
|
|
Ecliptasaponin A (Standard) is the analytical standard for Ecliptasaponin A (HY-N1508). Ecliptasaponin A is an orally active pentacyclic triterpenoid saponin. Ecliptasaponin A exerts anti-tumor activity by activating ASK1/JNK pathway, inducing apoptosis and autophagy in lung cancer cells. Ecliptasaponin A exerts anti-inflammatory/anti-fibrotic effects and protects the cardiovascular system by inhibiting the HMGB1/TLR4/NF-κB pathway, and the expression of COX-2 and MMP-9. Ecliptasaponin A can enhance SOD activity, reduce MDA levels, and alleviate oxidative stress damage. Ecliptasaponin A exerts chondroprotective effects by inhibiting the expression of MMP13 and regulating inflammatory factors. Ecliptasaponin A improves ovarian function and regulates sex hormones by upregulating the expression of ESR1 receptors.
|
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-145603S
-
|
|
|
Vanzacaftor-d4 (VX-121-d4) is the deuterium labeled Vanzacaftor (HY-145603). Vanzacaftor is an orally active noval corrector of Cystic fibrosis transmembrane conductance regulator (CFTR). Vanzacaftor improves processing and trafficking of CFTR protein as well as increases chloride transport in triple combined with Tezacaftor (HY-15448) and Deutivacaftor. Vanzacaftor-Tezacaftor-Deutivacaftor is safe and well tolerated, improving lung function, respiratory symptoms, and CFTR function with cystic fibrosis, which is promising for research in the field of cystic fibrosis diseases .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-150229
-
|
|
|
Cationic Lipids
|
|
306-N16B is a selective lung-targeted lipid nanoparticle that reversibly targets lung endothelial cells and specific immune cells through selective adsorption of a protein corona mediated by differences in tail structure (such as fibrinogen β/γ chain). 306-N16B binds to specific plasma proteins in the blood to form a protein corona, which guides the particles to be enriched in the lungs, releases mRNA and promotes target cell gene expression, exerts efficient lung cell transfection activity, and can precisely regulate gene delivery of different cell types in the lungs (such as endothelial cells and macrophages). 306-N16B can be used in gene therapy technologies for hereditary lung diseases including pulmonary lymphangioleiomyomatosis (LAM), restoring tumor suppressor function by delivering Tsc2 mRNA, and can also be used for lung-specific mRNA vaccines and gene editing therapies .
|
-
- HY-W839203
-
|
1,2-Didocosanoyl-sn-glycero-3-phosphocholine; PC(22:0/22:0)
|
|
Phospholipids
|
|
22:0 PC (1,2-Didocosanoyl-sn-glycero-3-phosphocholine), a type of phosphatidylcholine, functions as a lung surfactant and is characterized as an amphipathic molecule predominantly found in the outer leaflets of biological membrane bilayers.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
